Preparation and identification of a single-chain variable fragment antibody against Newcastle diseases virus F48E9

Vet Immunol Immunopathol. 2014 Oct 15;161(3-4):258-64. doi: 10.1016/j.vetimm.2014.08.009. Epub 2014 Aug 21.

Abstract

This article describes a proposed method for convenient and efficient detection of Newcastle diseases virus (NDV) that uses the fusion of single-chain variable fragment (scFv) and pOPE101 vector. In order to select the single chain variable fragment (scFv) against NDV F48E9, the total RNA was extracted from the spleen of immunized chicken, and then was converted into cDNA via the reverse transcription. The scFv was spliced by using splice-overlap extension polymerase chain reaction (SOE-PCR). The scFv gene was cloned into a pOPE101 vector and expressed in E. coli. Under the optimized conditions, antibody affinity was studied by indirect ELISA. One positive clone was selected by ELISA screening, named ZL.6. Based on the positive clone and the germline sequence, the results of sequence analysis showed that there are more variation in CDR of VH and VL. In addition, BHK21 cell culture was conducted to examine the potential antiviral activity of ZL.6. The experimental result demonstrated that ZL.6 was able to neutralize NDV F48E9 which infected BHK21 cells. So ZL.6 will be proved useful for further characterization of NDV as potential diagnostic tool and therapeutic agent.

Keywords: Antiviral activity; Newcastle diseases virus; Sequence comparison; scFv.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Viral / metabolism*
  • Chickens
  • Cloning, Molecular
  • Female
  • Molecular Sequence Data
  • Newcastle Disease / prevention & control
  • Newcastle disease virus / classification*
  • Newcastle disease virus / immunology*
  • RNA Splicing
  • RNA, Viral
  • Single-Chain Antibodies / metabolism*
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Viral
  • RNA, Viral
  • Single-Chain Antibodies
  • Viral Vaccines